Generics company Actavis loses lawsuit; NIH looking to fund drug delivery researchers;

> A New Jersey court ruled that Actavis ($ACT) generics violate 7 Depomed patents of its Gralise (gabapentin) tablets for the management of postherpetic neuralgia, which are based on its proprietary Acuform drug delivery technology. Release | Story

> Drug delivery specialist EastGate Acquisitions said that it is trying to acquire the licensing rights to develop and manufacture an intraoral insulin formulation. Release

> The FDA issued a Class I recall of Enhancement Medical's Expression intranasal splint, saying it is dangerous when injected subcutaneously, especially when used off-label as a dermal filler. Story

> The U.S. National Institutes of Health is inviting scientists to apply for funding of research into platform delivery technologies for nucleic acid therapeutics. Announcement

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.